x Health Men's Health Children's Health Nutrition and Wellness Reproductive Health Health & Science Digital News Videos Opinions Cartoons Education E-Paper Lifestyle & Entertainment Nairobian Entertainment Eve Woman Travelog TV Stations KTN Home KTN News BTV KTN Farmers TV Radio Stations Radio Maisha Spice FM Vybez Radio Enterprise BULK SMS E-Learning Digger Classified The Standard Group Corporate Contact Us Rate Card Vacancies DCX O.M Portal Corporate Email RMS
Login ×
BTV
VAS
DCX
RMS

New drug to boost women’s sex drive approved

Health & Science - By Reuters | June 22nd 2019 at 05:08:03 GMT +0300

The US drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra”.

The therapy, Vyleesi, will compete in a market which has seen previous attempts fail. Analysts have said that a drug that safely and effectively treats loss of sexual desire in women could eventually reach annual sales of about $1 billion.

Palatin’s shares jumped 44% to $1.93, while Amag shares rose 11.5% after market.

Vyleesi, chemically known as bremelanotide, activates pathways in the brain involved in sexual desire, helping premenopausal women with hypoactive sexual desire disorder (HSDD).

The drug will compete with Sprout Pharmaceuticals’ Addyi, a once-daily pill that was approved for HSDD in 2015 with a warning restricting alcohol use when on the medication. It will be available from September through select pharmacies.

Addyi was approved under intense pressure from advocacy groups despite a review by scientists at the Food and Drug Administration (FDA) that deemed it minimally effective and possibly unsafe.

Vyleesi, which does not restrict alcohol use, is seen as having several advantages over Addyi, including tolerable side effects, rapid-acting nature and not having to take it every day, according to analysts.

Side effects reported during clinical trials included mild to moderate nausea lasting no more than two hours and mostly occurred over the first three doses, Amag said. About 40% of patients in clinical trials experienced nausea.

The drug is administered as a shot into the abdomen or thigh using an auto-injector at least 45 minutes before anticipated sexual activity, with the FDA recommending patients not to take more than one dose within 24 hours or more than eight doses per month.

The drug was developed by Palatin and Amag holds exclusive North America sales rights. Palatin will get $60 million from Amag for the approval plus additional payments for certain sales milestones and royalties.

HSDD affects about 6 million women in the U.S., but few seek or receive treatment.

SVB Leerink analyst Ami Fadia said there will be a need for more direct-to-consumer advertising through social media, which could help in building awareness about HSDD.

“These women are just suffering in silence and so the market doesn’t really exist today,” Amag CEO William Heiden said.

Ladenburg Thalmann analyst Michael Higgins forecast Vyleesi sales could reach $732 million by 2030.

Top Stories

After weeping for doctors, Nyikal now defends his stint at MOH
Health & Science - By Japheth Ogila


810 new Covid-19 cases as Kenya inches towards 80,000
Health & Science - By Judah Ben-Hur


Kidney specialist Dr Were succumbs to Covid-19
Health & Science - By Mireri Junior


Nurses pile pressure as doctors' strike looms
Health & Science - By Graham Kajilwa


Poor girls sell sex to get money for sanitary products
Reproductive Health - By Kirsten Kanja


Parliament orders release of sh500 million for healthcare workers medical cover
Health & Science - By Graham Kajilwa


MP’s battle with Covid-19 at home
Health & Science - By Mercy Kahenda


MSF: HIV infection rate drops
Health & Science - By Mactilda Mbenywe


CDC may shorten Covid-19 quarantine period guidelines
Health & Science - By Reuters


KMPDU: Claims doctors are getting Covid-19 in bars insult to us
Health & Science - By Mercy Asamba


Latest Stories

Parliament orders release of sh500 million for healthcare workers medical cover
Health & Science - By Graham Kajilwa


Coronavirus remains infectious on surfaces for days by forming a 'pancake-like film'
Health & Science - By Mirror


Covid-19: Kenya records 780 new infections and 10 deaths
Health & Science - By Mercy Asamba


When should a person be pronounced dead?
Health & Science - By Graham Kajilwa


Nurses pile pressure as doctors' strike looms
Health & Science - By Graham Kajilwa


CDC may shorten Covid-19 quarantine period guidelines
Health & Science - By Reuters


Detaining patients over bills is wrong, WHO tells hospitals
Health & Science - By Mercy Kahenda


MSF: HIV infection rate drops
Health & Science - By Mactilda Mbenywe


810 new Covid-19 cases as Kenya inches towards 80,000
Health & Science - By Judah Ben-Hur


You have deserted us, health unions say
Health & Science - By Grace Ng'ang'a


//

Stay Ahead!

Access premium content only available
to our subscribers.

Support independent journalism
×
Log in
Support independent journalism
Create an account    Forgot Password
Create An Account
Support independent journalism
I have an account Log in
Reset Password
Support independent journalism
Log in